HRP20161436T1 - Spojevi za liječenje bolesti povezanih sa ishemijom-reperfuzijom - Google Patents
Spojevi za liječenje bolesti povezanih sa ishemijom-reperfuzijom Download PDFInfo
- Publication number
- HRP20161436T1 HRP20161436T1 HRP20161436TT HRP20161436T HRP20161436T1 HR P20161436 T1 HRP20161436 T1 HR P20161436T1 HR P20161436T T HRP20161436T T HR P20161436TT HR P20161436 T HRP20161436 T HR P20161436T HR P20161436 T1 HRP20161436 T1 HR P20161436T1
- Authority
- HR
- Croatia
- Prior art keywords
- 8alkyl
- aryl
- side chains
- group
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 18
- 208000028867 ischemia Diseases 0.000 title claims 5
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 238000004321 preservation Methods 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- IINGFDPJAKOGIN-SRQIZXRXSA-N (1r,5s,6s)-3-ethyl-4-oxo-7,8-dioxa-3-azabicyclo[3.2.1]octane-6-carboxylic acid Chemical compound O=C1N(CC)C[C@H]2O[C@H](C(O)=O)[C@@H]1O2 IINGFDPJAKOGIN-SRQIZXRXSA-N 0.000 claims 2
- JYNNXEMXMQLLMC-QJPTWQEYSA-N (1s,5r,6r)-3-[(4-methoxyphenyl)methyl]-4-oxo-7,8-dioxa-3-azabicyclo[3.2.1]octane-6-carboxylic acid Chemical compound C1=CC(OC)=CC=C1CN1C(=O)[C@H](O2)[C@H](C(O)=O)O[C@H]2C1 JYNNXEMXMQLLMC-QJPTWQEYSA-N 0.000 claims 2
- JBRUIYKDCGYKTK-HBNTYKKESA-N (1s,5r,6r)-3-benzyl-4-oxo-7,8-dioxa-3-azabicyclo[3.2.1]octane-6-carboxylic acid Chemical compound C([C@@H]1O[C@H]([C@H](C2=O)O1)C(=O)O)N2CC1=CC=CC=C1 JBRUIYKDCGYKTK-HBNTYKKESA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- VVAKEQGKZNKUSU-UHFFFAOYSA-N 2,3-dimethylaniline Chemical group CC1=CC=CC(N)=C1C VVAKEQGKZNKUSU-UHFFFAOYSA-N 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000004900 autophagic degradation Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004941 influx Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000006213 oxygenation reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
Claims (15)
1. Spoj formule (I)
[image]
u kojoj
R1 je izabran iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C1-8alkenil, C2-8alkinil, cikloalkil, aril, heterociklus -C1-8alkil-aril, -C1-8alkil-heterociklus, -C1-8alkil-NH2, - aril-NH2, -C1-8alkil-O-aril, -aril-OH, C1-8alkil-OH, -COOR, -C1-8alkil-OR, metiloksikarbonil-C1-8alkil, karboalkiloksi-aril alkil karbamoil aril i -(bočnih lanaca aminokiselina);
R2 je izabran iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C2-8alkenil, C2-8alkinil, cikloalkil, aril, -C1-8alkil-aril, -C1-8alkil-heterociklus, -C1-8alkil-NRR’, -aril-NRR’, - C1-8alkil-OR, -C1-8alkil-COOR, -C1-8alkil-OC(O)R, -C1-8alkil-N(R)C(O)R’, -aril-OR, -aril-COOR, -aril-COR, -aril-OC(O)R, -aril-N(R)C(O)R’, -CH(bočni lanci aminokiselina)V CO2R, -CH(bočni lanci aminokiselina)C(O)NR, -CH(CO2R)-bočni lanci aminokiselina i CH(CONRR’)-bočni lanci aminokiselina,
R3 je COOH;
R i R’, međusobno isti ili različiti, su izabrani iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C2-8alkenil, C2-8alkinil, cikloalkil, aril, heterociklus, -C1-8alkil-aril; -C1-8heterociklus alkil; zaštitne grupe, -C(O)CH-(bočni lanci aminokiselina)-NHT, -NH-CH(bočni lanci aminokiselina)COOT i -CH(bočni lanci aminokiselina)COOT,
gdje T je izabran od H i C1-8alkil; R i R’ međusobno spojeni mogu formirati cikloalkil;
i gdje gore navedene alkil, alkenil, alkinil, cikloalkil, aril, heterociklus grupe mogu biti supstituirane sa jednom ili više grupa izabranih iz grupe koja se sastoji od halogena, CN, NO2, NH2, OH, COOH, CO i C1-6alkil;
isključujući spojeve (1S,5R,7S)-3-etil-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu, (1R,5S,7R)-3-(p-metoksibenzil)-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu, (1R,5S,7R)-3-Benzil-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu i (1R,5S,7R)-3-(p-fenil)-benzil-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu.
2. Spoj prema patentnom zahtjevu 1, naznačen time što
R1 je izabran iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C1-8alkenil, -C1-8alkilfenil, -C1-8alkil-OH i -C1-8alkil-OR;
R2 je izabran iz grupe koja se sastoji od arila, -C1-8alkil-arila;
3. Spoj prema patentnom zahtjevu 2, naznačen time što
R1 je H, Me, =CH2, CH2Ph, CH2OH, CH2OBn;
R2 je Ph, CH2Ph, CHPh2.
4. Spojevi prema patentnom zahtjevu 2, formule (Ia)
[image]
u kojoj
[image]
ili formule (Ib)
[image]
u kojoj
[image]
5. Spoj formule (I) prema bilo kojem od patentnih zahtjeva 1-4, koje također obuhvaća spojeve (1S,5R,7S)-3-etil-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu, (1 R,5S,7R)-3-(p-metoksibenzil)-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu, (1R,5S,7R)-3-Benzil-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu i (1R,5S,7R)-3-(p-fenil)-benzil-2-okso-6,8-dioksa-3-azabiciklo[3.2.1]oktan-7-karboksilnu kiselinu za uporabu kao lijek.
6. Spoj formule (I)
[image]
u kojoj
R1 je izabran iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C1-8alkenil, C2-8alkinil, cikloalkil, aril, heterociklus, -C1-8alkil-aril, -C1-8alkil-heterociklus, -C1-8alkil-NH2, - aril-NH2, -C1-8alkil-O-aril, -aril-OH, C1-8alkil-OH, -COOR, -C1-8alkil-OR, metiloksikarbonil-C1-8alkil, karboalkiloksi-aril, alkil karbamoil aril i -(bočnih lanaca aminokiselina);
R2 je izabran iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C2-8alkenil, C2-8alkinil, cikloalkil, aril, -C1-8alkil-aril, -C1-8alkil-heterociklus, -C1-8alkil-NRR’, -aril-NRR’, - C1-8alkil-OR, -C1-8alkil-COOR, -C1-8alkil-OC(O)R, -C1-8alkil-N(R)C(O)R’, -aril-OR, -aril-COOR, -aril-COR, -aril-OC(O)R, -aril-N(R)C(O)R’, -CH(bočni lanci aminokiselina)CO2R, -CH(bočni lanci aminokiselina)C(O)NR, -CH(CO2R)-bočni lanci aminokiselina i CH(CONRR’)-bočni lanci aminoksielina,
R3 je izabran iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C2-8alkenil, C2-8alkinil, cikloalkil, aril, -C1-8alkil-aril, heterociklus, -C1-8alkil-heterociklus; -C(O)R, - C(O)OR, -C(O)NRR’, CH2OR, CH2NRR’, -C(O)NH-CH(bočni lanci aminokiselina)C(O)OR, CH2NR-Fmoc, CH2NR-Boc i CH2NR-CBz,
R i R’, međusobno isti ili različiti, su izabrani iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C2-8alkenil, C2-8alkinil, cikloalkil, aril, heterociklus, -C1-8alkil-aril; -C1-8heterociklus alkil; zaštitne grupe, -C(O)CH-(bočnih lanaca aminokiselina)-NHT, -NH-CH(bočni lanci aminokiselina)COOT i -CH(bočni lanci aminokiselina)COOT,
gdje je T izabran od H i C1-8alkil; R i R’ međusobno kombinirani mogu formirati cikloalkil;
i gdje gore navedene alkil, alkenil, alkinil, cikloalkil, aril, heterociklične grupe mogu biti supstituirane sa jednom ili više grupa izabranih iz grupe koja se sastoji od halogena, CN, NO2, NH2, OH, COOH, CO i C1-6alkila;
za uporabu u liječenju patologija povezanih sa ishemijom-reperfuzijom ili za uporabu u medicinskim procedurama koje uključuju ishemiju-reperfuziju.
7. Spoj za uporabu prema patentnom zahtjevu 6, naznačen time što R1 je izabran iz grupe koja se sastoji od slijedećih: H, C1-8alkil, C1-8alkenil, -C1-8alkilfenil, -C1-8alkil-OH i -C1-8alkil-OR;
R2 je izabran iz grupe koja se sastoji od arila i -C1-8alkil-arila;
R3 je izabran iz grupe koja se sastoji od C(O)OR, -C(O)NRR’;
R i R’, međusobno isti ili različiti, su izabrani iz grupe koja se sastoji od slijedećih: H, C1-8alkil, -C1-8alkil-NH2, -C1-8alkil-OH; R i R’ međusobno kombinirani mogu formirati cikloalkil.
8. Spoj za uporabu prema patentnom zahtjevu 7, naznačen time što
R1 je H, Me, =CH2, CH2Ph, CH2OH, CH2OBn;
R2 je Ph, CH2Ph, CHPh2;
R3 je COOH, COOMe, CONHCH2CH2NH2, CONHCH2CH2OH,
[image]
9. Spoj za uporabu prema patentnom zahtjevu 8, naznačen formulom (Ia)
[image]
u kojoj
[image]
[image]
ili naznačen formulom (Ib)
[image]
u kojoj
[image]
[image]
10. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 6-9, naznačen time što su navedene patologije ili medicinske procedure izabrane od:
- akutne ishemije miokarda;
- ishemije centralnog živčanog sustava (CNS) uzrokovane trombozom ili embolijom u cerebralnom području intrakranijalnih arterija ili srčanim zastojem, uključujući stalan ili privremeni prekid protoka krvi u nekim cerebralnim arterijskim područjima ili u cijelom encefalonu;
- svih drugih ishemijskih patologija naznačenih sniženim ili zaustavljenim protokom krvi nakon čega slijedi ponovno uspostavljanje influksa kisika i/ili hranljivih tvari do tkiva;
- stanja hipoksije cerebralnog tkiva kod kojih normalne razine oksigenacije mogu biti ponovo uspostavljene pomoću medicinske intervencije, kao što su na primjer, trovanje ili gušenje ugljičnim monoksidom;
- oštećenja drugih tkiva uzrokovana hipoksijom, ishemijom ili traumom, sposobna da izazovu smrt apoptozom ili autofagijom, do točke generiranja značajnih anatomskih i funkcionalnih lezija.
11. Spojevi za uporabu prema bilo kojem od patentnih zahtjeva 6-9, naznačeni time što su navedene patologije ili medicinske procedure izabrane od:
- kirurških procedura u kojima operacija osigurava da određena arterijska područja budu privremeno zatvorene, kao što se na primjer javlja u operaciji ablacije bubrežnog tumora;
- protokola eksplantacije, prezervacije i ponovne implantacije za organe namijenjene za transplantaciju, kao što su bubrezi, srce, pluća, jetra, crijevo, itd.;
- kronične traumatske encefalopatije (CTE).
12. Farmaceutska kompozicija koja sadrži najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 6-11.
13. Medij stanične kulture koji sadrži najmanje jedan spoj formule (I) kao što je opisano u bilo kojem od patentnih zahtjeva 6-9.
14. Sredstva za čuvanje za prezervaciju eksplantiranih organa namijenjenih za transplantaciju, pri čemu navedena sredstva za čuvanje sadrže najmanje jedan spoj formule (I) kao što je opisano u bilo kojem od patentnih zahtjeva 6-9.
15. Spoj formule (I), kao što je opisano u bilo kojem od patentnih zahtjeva 6-9, označen pogodnim reagensom, za uporabu u bilo kojoj proceduri korisnoj za svrhe medicinskog snimanja, za analize za snimanje in vitro ili in vivo tkiva i organa, za procjenu i kvantitativno određivanje ishemične-reperfuzione povrede i za praćenje uporabu i efikasnosti lijekova.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000062A ITFI20120062A1 (it) | 2012-03-21 | 2012-03-21 | Componenti per il trattamento di malattie correlate a ischemia-riperfusione. |
| EP13721085.2A EP2855487B1 (en) | 2012-03-21 | 2013-03-20 | Compounds for the treatment of ischemia-reperfusion- related diseases |
| PCT/IB2013/052205 WO2013140348A1 (en) | 2012-03-21 | 2013-03-20 | Compounds for the treatment of ischemia-reperfusion- related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161436T1 true HRP20161436T1 (hr) | 2017-01-13 |
Family
ID=46147570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161436TT HRP20161436T1 (hr) | 2012-03-21 | 2016-11-02 | Spojevi za liječenje bolesti povezanih sa ishemijom-reperfuzijom |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9932352B2 (hr) |
| EP (1) | EP2855487B1 (hr) |
| JP (2) | JP6382791B2 (hr) |
| KR (2) | KR20150014910A (hr) |
| CN (1) | CN104395321B (hr) |
| AU (2) | AU2013237021B2 (hr) |
| CA (1) | CA2907652C (hr) |
| CY (1) | CY1118282T1 (hr) |
| DK (1) | DK2855487T3 (hr) |
| EA (1) | EA033160B1 (hr) |
| ES (1) | ES2601384T3 (hr) |
| HR (1) | HRP20161436T1 (hr) |
| HU (1) | HUE031535T2 (hr) |
| IL (1) | IL234796B (hr) |
| IN (1) | IN2014CH07744A (hr) |
| IT (1) | ITFI20120062A1 (hr) |
| LT (1) | LT2855487T (hr) |
| ME (1) | ME02553B (hr) |
| PL (1) | PL2855487T3 (hr) |
| PT (1) | PT2855487T (hr) |
| RS (1) | RS55337B1 (hr) |
| SI (1) | SI2855487T1 (hr) |
| SM (1) | SMT201700055B (hr) |
| WO (1) | WO2013140348A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| IT202000008125A1 (it) * | 2020-04-16 | 2021-10-16 | Minerva Srl | Acidi carbossilici 3-aza-biciclo[3.2.1]ottani e loro derivati per l’uso nel trattamento di infiammazioni |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR75910B (hr) | 1981-04-21 | 1984-08-02 | Delalande Sa | |
| DE60042585D1 (de) | 2000-02-29 | 2009-09-03 | Univ Firenze | 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken |
| ITFI20020107A1 (it) * | 2002-06-19 | 2003-12-19 | Antonio Guarna | Composizioni farmaceutiche atte all'uso nel trattamento di patologie correlate all'azione di neutrofine e composti attivi in esse contenuti |
| KR20050028036A (ko) * | 2002-07-18 | 2005-03-21 | 화이자 프로덕츠 인크. | Ｃｃｒ1 케모카인 수용체의 길항제로서 비시클릭 피페리딘유도체 |
| WO2006015183A2 (en) * | 2004-07-30 | 2006-02-09 | Axonyx, Inc. | Pharmaceutical compositions for treating disorders of the skin |
| EP2189462B9 (en) * | 2008-11-25 | 2012-06-13 | Universita' Degli Studi di Firenze | Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases |
-
2012
- 2012-03-21 IT IT000062A patent/ITFI20120062A1/it unknown
-
2013
- 2013-03-20 SI SI201330411A patent/SI2855487T1/sl unknown
- 2013-03-20 ME MEP-2016-251A patent/ME02553B/me unknown
- 2013-03-20 RS RS20160926A patent/RS55337B1/sr unknown
- 2013-03-20 WO PCT/IB2013/052205 patent/WO2013140348A1/en active Application Filing
- 2013-03-20 EP EP13721085.2A patent/EP2855487B1/en active Active
- 2013-03-20 US US14/387,015 patent/US9932352B2/en active Active
- 2013-03-20 LT LTEP13721085.2T patent/LT2855487T/lt unknown
- 2013-03-20 KR KR1020147029365A patent/KR20150014910A/ko active Application Filing
- 2013-03-20 DK DK13721085.2T patent/DK2855487T3/en active
- 2013-03-20 CN CN201380026577.3A patent/CN104395321B/zh active Active
- 2013-03-20 EA EA201401045A patent/EA033160B1/ru unknown
- 2013-03-20 JP JP2015501034A patent/JP6382791B2/ja active Active
- 2013-03-20 HU HUE13721085A patent/HUE031535T2/en unknown
- 2013-03-20 PT PT137210852T patent/PT2855487T/pt unknown
- 2013-03-20 ES ES13721085.2T patent/ES2601384T3/es active Active
- 2013-03-20 KR KR1020207012664A patent/KR102181346B1/ko active IP Right Grant
- 2013-03-20 AU AU2013237021A patent/AU2013237021B2/en active Active
- 2013-03-20 CA CA2907652A patent/CA2907652C/en active Active
- 2013-03-20 PL PL13721085T patent/PL2855487T3/pl unknown
-
2014
- 2014-09-22 IL IL234796A patent/IL234796B/en active IP Right Grant
- 2014-10-21 IN IN7744CH2014 patent/IN2014CH07744A/en unknown
-
2016
- 2016-11-02 HR HRP20161436TT patent/HRP20161436T1/hr unknown
- 2016-11-03 CY CY20161101112T patent/CY1118282T1/el unknown
-
2017
- 2017-01-25 SM SM201700055T patent/SMT201700055B/it unknown
- 2017-11-21 AU AU2017265037A patent/AU2017265037B2/en active Active
- 2017-12-12 US US15/839,148 patent/US20180155363A1/en not_active Abandoned
-
2018
- 2018-06-27 JP JP2018122052A patent/JP2018168173A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502130A5 (hr) | ||
| JP2015503527A5 (hr) | ||
| JP2010511632A5 (hr) | ||
| EA202190567A1 (ru) | Специальные комбинированные композиции ингаляционного нинтеданиба и солей нинтеданиба | |
| RU2015120478A (ru) | Пери-карбинолы | |
| ES2929539T3 (es) | Sal formada por ácido 2-(1-aciloxipentil) benzoico mediante un aminoácido básico o aminoguanidina, método de preparación y usos de la misma | |
| JP2018522867A5 (hr) | ||
| HRP20161436T1 (hr) | Spojevi za liječenje bolesti povezanih sa ishemijom-reperfuzijom | |
| WO2018064953A1 (zh) | Idhp在制备预防和治疗冠状动脉粥样硬化疾病药物或保健品中的应用 | |
| RU2015113597A (ru) | Производные аминоизохинолина в качестве ингибиторов протеинкиназы | |
| Hu et al. | Pyruvate as a novel carrier of hydroxyethyl starch 130/0.4 may protect kidney in rats subjected to severe burns | |
| US20170157162A1 (en) | Nucleobase analogue derivatives and their applications | |
| CN109806263A (zh) | 一种药物组合物及其制备方法和用途 | |
| TWI391131B (zh) | ３－（２，２，２－三甲基肼）丙酸鹽的新用途 | |
| ES2687234T3 (es) | Agente de contraste para obtener imágenes de perfusión de miocardio | |
| CN106232108A (zh) | 治疗特发性肺纤维化的方法 | |
| CN104478798B (zh) | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 | |
| CN105130964A (zh) | 一种可用于制备治疗心血管疾病药物的化合物及其制备方法、用途 | |
| EP4199973A1 (en) | Composition comprising polyethylene glycol conjugated to indocyanine green and methods of use | |
| CN104415033B (zh) | 取代唑类化合物作为制备抗肿瘤药物的应用 | |
| CN116650489A (zh) | 认知功能障碍模型、用途及化合物mt-1207在防治认知障碍方面的应用 | |
| WO2017156222A1 (en) | Radiomitigating compounds, compositions and methods related thereto | |
| UA120722C2 (uk) | ЕТИЛ-[2-(2-АМІНО-3-ЦІАНО-5,5-ДІОКСИДО-4Н-ПІРАНО[3,2-с][1,2]БЕНЗОКСАТІЇН-4-ІЛ)ФЕНОКСІ]АЦЕТАТ, ЩО ВИЯВЛЯЄ ГЕМОСТАТИЧНУ АКТИВНІСТЬ | |
| TW200418814A (en) | Cardioprotective delta opioid receptor agonists and methods of using same | |
| CN103396376A (zh) | 一种抗菌抗癌活性化合物 |